David Andrew

David Andrew has extensive work experience in the field of immunology and immune-oncology. David is currently working as a Senior Director of Immunology at Normunity since May 2022. Prior to this, they served as a Senior Director of Lead Identification at Tri-Institutional Therapeutics Discovery Institute, Inc. from September 2018. In this role, they led a group in generating and characterizing monoclonal antibodies and phage in the areas of immune-oncology, oncology, and immunology.

Before that, David worked as a Consultant in Immunology and Immune-Oncology at a biotech company from November 2014 to July 2018. David was also the VP of Research at ImmuNext from April 2014 to October 2014, where they coordinated various cancer immunotherapy and autoimmune programs. During this time, they also collaborated with Johnson and Johnson on an anti-VISTA project.

David has also worked as a Consultant in Immunology and ABDEV, where they provided advisory services and participated in due diligence for immunology and antibody development projects. David has experience evaluating small biotech immunology programs for venture capital investments.

Furthermore, David has held positions at Boehringer Ingelheim as a Senior Research Fellow from January 2011 to September 2012, where they led various biologic programs and developed in vitro immunology assays. David also worked as a Senior Research Scientist II Oncology at Agensys (Astellas) from August 2009 to January 2011, focusing on oncology target discovery/validation and biomarker research.

Prior to that, David was an Associate Director of Antibody Development at PDL BioPharma from August 2006 to February 2009. In this role, they were responsible for generating monoclonal antibodies for target validation in immunology and oncology, as well as supporting pre-clinical and clinical studies with mAbs.

David's career began at GSK in August 2001, where they served as a Section Leader of Immunology. David led a group providing in vitro and in vivo immunology support for respiratory inflammation programs, including target validation and selection of lead candidates.

Overall, David Andrew has a diverse background and extensive expertise in immunology, immune-oncology, antibody development, and target validation.

David Andrew has a PhD in Immunology from University College London. David also completed a postdoctoral fellowship in Lymphocyte Trafficking at Stanford University. However, specific start and end years for both these educational experiences were not provided.